Evidence map›Paper›PMID 39240321›Full record

ArticleCurrent microbiology2024

Novel Fabrication of Bio-polymeric Nanogel Loaded with Nalidixic Acid Formulations for the Effective Prevention of Bacterial Pathogens Leading Urinary Tract Infection and Its Biosafety Evaluation.

Huili Yang, Juan Meng, Lixia Shi

Abstract read
PubMed Publisher
In one paragraph

Article in Current microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Huili YangDepartment of Obstetrics, Central Hospital affiliated to Shandong First Medical University, 105 Jiefang Road, Jinan, 250013, Shandong, China.ORCID http://orcid.org/0009-0001-9320-463X
Juan MengDepartment of Obstetrics, Central Hospital affiliated to Shandong First Medical University, 105 Jiefang Road, Jinan, 250013, Shandong, China.ORCID http://orcid.org/0009-0003-1590-1071
Lixia ShiDepartment of Obstetrics, Central Hospital affiliated to Shandong First Medical University, 105 Jiefang Road, Jinan, 250013, Shandong, China. slx780122@163.com.ORCID http://orcid.org/0009-0008-2414-8276

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Management of urinary tract infections (UTI) is a highly challenging process due to the biofilm-forming ability of human-pathogenic bacteria. Here, we designed to fabricate an effective nanogel with a combination of chitosan bio-polymer and nalidixic acid to prevent biofilm-forming bacterial pathogens. Chitosan-coated nalidixic acid nanogel (NA@CS) exhibits outstanding inhibition potential against bacterial strains. In vitro, anti-bacterial analysis methods (well diffusion, colony-forming assay, and anti-biofilm assay) were performed to study the bacterial inhibition potential of prepared nanogel, which reveals that NA@CS nanogel have greater inhibition potential against selected pathogens. The combination of nalidixic acid with chitosan biopolymer decreases the virulence and pathogenicity of biofilm-forming pathogens due to their ability to membrane phospholipids penetration. Furthermore, the fabricated NA@CS nanogel showed reliable in vitro bio-compatibility on L929 fibroblast cells and in vivo compatibility with Artemia salina animal model. Overall, the results demonstrate that NA@CS nanogel could be an effective therapeutic for treating urinary tract infections and urine bladder wound healing.

Indexed as

Anti-Bacterial AgentsBiofilmsChitosanNalidixic AcidNanogelsUrinary Tract InfectionsAnimalsArtemiaBacteriaCell LineHumansMiceMicrobial Sensitivity TestsAnti-Bacterial AgentsChitosanNalidixic AcidNanogels

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.